Company news

Neurocrine Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia

December 4, 2023

Neurocrine Biosciences to Host Analyst Day on December 5, 2023

November 30, 2023

Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

November 12, 2023

Neurocrine Biosciences Provides Development Pipeline Update

November 8, 2023

Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference

November 7, 2023

Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia

November 7, 2023

Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023

November 1, 2023

Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

October 30, 2023

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results

October 9, 2023

Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

October 4, 2023

Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

September 20, 2023

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

September 13, 2023

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

September 11, 2023

Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

September 10, 2023

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

September 10, 2023

Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine)...

August 28, 2023

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

August 27, 2023

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

August 17, 2023

Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

July 31, 2023

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results

July 10, 2023

Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors

July 10, 2023

Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023

June 14, 2023

Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 7, 2023

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

June 1, 2023

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology

May 18, 2023

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Soc...

May 14, 2023

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

May 11, 2023

Neurocrine Biosciences Reports First Quarter 2023 Financial Results

May 2, 2023

Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference

May 1, 2023

Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week

April 30, 2023

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results

April 11, 2023

Neurocrine Biosciences to Present at the Stifel 2023 CNS Days

March 20, 2023

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference

March 8, 2023

Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning

March 8, 2023

Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting

March 2, 2023

Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

February 5, 2023

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results

January 16, 2023

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases

January 8, 2023

Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

December 21, 2022

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep

December 5, 2022

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

December 1, 2022

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

November 7, 2022

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting

November 2, 2022

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

November 2, 2022

Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

October 31, 2022

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

October 26, 2022

Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022

October 23, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 40 decks. Every deck is listed under its year.